← brief for 2026-10-15 · Slowing decline

Analytical Characterization, Pharmacokinetics, Safety, and Preliminary Immunogenicity of GNR-062, an Agalsidase Beta Biosimilar Candidate, in Healthy Male Volunteers

Key takeaways

This small trial tested a new drug for Fabry disease, a rare condition that can damage the kidneys. The study involved healthy male volunteers to check safety and how the body handles the drug. It is a small step toward a new treatment option. The results show the drug is safe in this group, but more testing in people with the disease is needed.

Who did this work

Ivan V. Lyagoskin (Vladimir State University) · Maksim Smolov (Vladimir State University) · Oksana Markova (Vladimir State University) · Vladislav Klyashtorny (Vladimir State University) · Marina Pantyushenko (Vladimir State University) · M. A. Koroleva (Vladimir State University) · Olga M. Strizhakova (Vladimir State University) · Rahim R. Shukurov (Vladimir State University) · Хамитов Равиль Авгатович (Vladimir State University)

Source

Article · OpenAlex, CKD works · 2026-10-14
https://doi.org/10.3390/biotech15040094